How generalisable to community samples are clinical trial results for treatment of nicotine dependence: A comparison of common eligibility criteria with respondents of a large representative general population survey

Tobacco Control

Volumn 20, Issue 5, 2011, Pages 338-343

  le Strat, Yann ^a,b,c,d   Rehm, Jürgen ^a,e,f   le Foll, Bernard ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b INSERM   (France)

^c HÔPITAL LOUIS MOURIER   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e UNIVERSITY OF TORONTO   (Canada)

^f DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HEALTH SURVEY; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; MOTIVATION; PATIENT SELECTION; PSYCHIATRIC DIAGNOSIS; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT OUTCOME; UNITED STATES;

ADOLESCENT; ADULT; AGED; DIAGNOSIS, DUAL (PSYCHIATRY); DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; MOTIVATION; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SMOKING CESSATION; TOBACCO USE DISORDER; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84860388862     PISSN: 09644563     EISSN: 14683318     Source Type: Journal    
DOI: 10.1136/tc.2010.038703     Document Type: Article

References (99)

1. Fiore MC, Jaén CR, Baker TB. Treating Tobacco Use and Dependence: 2008 Update. US Dept of Health and Human Services, 2008.
2. Le Foll B, George TP. Treatment of tobacco dependence: integrating recent progress into practice. CMAJ 2007; 177: 1373-80.
3. Le Foll B, Melihan-Cheinin P, Rostoker G, et al; Working Group of AFSSAPS. Smoking cessation guidelines: evidence-based recommendations of the French Health Products Safety Agency. Eur Psychiatry 2005; 20: 431-41.
4. National Institute for Clinical Excellence. Brief Interventions and Referral for Smoking Cessation in Primary Care and Other Settings. Public Health Intervention Guidance No. 1. London: NICE, 2006.
5. Weisberg HI, Hayden VC, Pontes VP. Selection criteria and generalizability within the counterfactual framework: explaining the paradox of antidepressant-induced suicidality? Clin Trials 2009; 6: 109-18.
6. Dzewaltowski DA, Estabrooks PA, Klesges LM, et al. Behavior change intervention research in community settings: how generalizable are the results? Health Promot Int 2004; 19: 235-45.
7. Kamholz BW, Gulliver SB, Helstrom A, et al. Implications of participant self-selection for generalizability: who participates in smoking laboratory research? Subst Use Misuse 2009; 44: 343-56.
8. Weiss NS, Koepsell TD, Psaty BM. Generalizability of the results of randomized trials. Arch Intern Med 2008; 168: 133-5.
9. Dhruva SS, Redberg RF. Variations between clinical trial participants and Medicare beneficiaries in evidence used for Medicare national coverage decisions. Arch Intern Med 2008; 168: 136-40.
10. Blanco C, Olfson M, Goodwin RD, et al. Generalizability of clinical trial results for major depression to community samples: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2008; 69: 1276-80.
11. Zimmerman M, Chelminski I, Posternak MA. Generalizability of antidepressant efficacy trials: differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trial. Am J Psychiatry 2005; 162: 1370-2.
12. Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry 2002; 159: 469-73.
13. Posternak MA, Zimmerman M, Keitner GI, et al. A reevaluation of the exclusion criteria used in antidepressant efficacy trials. Am J Psychiatry 2002; 159: 191-200.
14. Zetin M, Hoepner CT. Relevance of exclusion criteria in antidepressant clinical trials: a replication study. J Clin Psychopharmacol 2007; 27: 295-301.
15. Boter H, Derks EM, Fleischhacker WW, et al. Generalizability of the results of efficacy trials in first-episode schizophrenia: comparisons between subgroups of participants of the European First Episode Schizophrenia Trial (EUFEST). J Clin Psychiatry 2010; 71: 58-65.
16. Leucht S, Heres S, Hamann J, et al. Methodological issues in current antipsychotic drug trials. Schizophr Bull 2008; 34: 275-85.
17. Khan AY, Preskorn SH, Baker B. Effect of study criteria on recruitment and generalizability of the results. J Clin Psychopharmacol 2005; 25: 271-5.
18. Blanco C, Olfson M, Okuda M, et al. Generalizability of clinical trials for alcohol dependence to community samples. Drug Alcohol Depend 2008; 98: 123-8.
19. Humphreys K, Weingardt KR, Harris AH. Influence of subject eligibility criteria on compliance with National Institutes of Health guidelines for inclusion of women, minorities, and children in treatment research. Alcohol Clin Exp Res 2007; 31: 988-95.
20. Humphreys K, Weingardt KR, Horst D, et al. Prevalence and predictors of research participant eligibility criteria in alcohol treatment outcome studies, 1970-98. Addiction 2005; 100: 1249-57.
21. Humphreys K, Weisner C. Use of exclusion criteria in selecting research subjects and its effect on the generalizability of alcohol treatment outcome studies. Am J Psychiatry 2000; 157: 588-94.
22. Okuda M, Hasin DS, Olfson M, et al. Generalizability of clinical trials for cannabis dependence to community samples. Drug Alcohol Depend 2010; 111: 177-81.
23. Andrews JA, Severson HH, Akers L, et al. Who enrolls in a self-help cessation program for smokeless tobacco? Addict Behav 2001; 26: 757-64.
24. Graham AL, Bock BC, Cobb NK, et al. Characteristics of smokers reached and recruited to an internet smoking cessation trial: a case of denominators. Nicotine Tob Res 2006; (8 Suppl 1): S43-8.
25. Howard-Pitney B, Fortmann SP, Killen JD. Generalizability of findings from a chewing tobacco cessation clinical trial. Nicotine Tob Res 2001; 3: 347-52.
26. Hughes JR. Data to estimate the similarity of tobacco research samples to intended populations. Nicotine Tob Res 2004; 6: 177-9.
27. Hughes JR, Callas PW. Data to assess the generalizability of samples from studies of adult smokers. Nicotine Tob Res 2010; 12: 73-6.
28. Robinson ML, Schroeder JR, Moolchan ET. Adolescent smokers screened for a nicotine replacement treatment trial: correlates of eligibility and enrollment. Nicotine Tob Res 2006; 8: 447-54.
29. Schmelzle J, Rosser WW, Birtwhistle R. Update on pharmacologic and nonpharmacologic therapies for smoking cessation. Can Fam Physician 2008; 54: 994-9.
30. Fagerstrom KO. Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav 1978; 3: 235-41.
31. Grant BF, Dawson DA, Stinson FS, et al. The Alcohol Use Disorder and Associated Disabilities Interview Schedule-IV (AUDADIS-IV): reliability of alcohol consumption, tobacco use, family history of depression and psychiatric diagnostic modules in a general population sample. Drug Alcohol Depend 2003; 71: 7-16.
32. Grant BF, Dawson DA, Stinson FS, et al. The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002. Drug Alcohol Depend 2004; 74: 223-34.
33. Gorwood P. Clinical assessment in psychiatric genetics. In: Leboyer M, Bellivier F, eds. Psychiatric Genetics: Methods and Protocols: John M Walker. Totowa, NJ: Humana Press Inc, 2003: 99-126.
34. Grant B, Hasin D, Chou S, et al. Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 2004; 61: 1107-15.
35. Grant BF, Harford TC, Dawson DA, et al. The Alcohol Use Disorder and Associated Disabilities Interview schedule (AUDADIS): reliability of alcohol and drug modules in a general population sample. Drug Alcohol Depend 1995; 39: 37-44.
36. Eisenberg MJ, Filion KB, Yavin D, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ 2008; 179: 135-44.
37. Tsai ST, Cho HJ, Cheng HS, et al. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther 2007; 29: 1027-39.
38. Nakamura M, Oshima A, Fujimoto Y, et al. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther 2007; 29: 1040-56.
39. Fossati R, Apolone G, Negri E, et al. A double-blind, placebo-controlled, randomized trial of bupropion for smoking cessation in primary care. Arch Intern Med 2007; 167: 1791-7.
40. Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006; 166: 1571-7.
41. Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006; 166: 1561-8.
42. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 56-63.
43. Gonzales D, Rennard SI, Nides M, et al; Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 47-55.
44. Holt S, Timu-Parata C, Ryder-Lewis S, et al. Efficacy of bupropion in the indigenous Maori population in New Zealand. Thorax 2005; 60: 120-3.
45. Cooper TV, Klesges RC, Debon MW, et al. A placebo controlled randomized trial of the effects of phenylpropanolamine and nicotine gum on cessation rates and postcessation weight gain in women. Addict Behav 2005; 30: 61-75.
46. Dalsgareth OJ, Hansen NC, Soes-Petersen U, et al. A multicenter, randomized, double-blind, placebo-controlled, 6-month trial of bupropion hydrochloride sustained-release tablets as an aid to smoking cessation in hospital employees. Nicotine Tob Res 2004; 6: 55-61.
47. Collins BN, Wileyto EP, Patterson F, et al. Gender differences in smoking cessation in a placebo-controlled trial of bupropion with behavioral counseling. Nicotine Tob Res 2004; 6: 27-37.
48. Aubin HJ, Lebargy F, Berlin I, et al. Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial. Addiction 2004; 99: 1206-18.
49. Tonnesen P, Tonstad S, Hjalmarson A, et al. A multicentre, randomized, doubleblind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. J Intern Med 2003; 254: 184-92.
50. Glavas D, Rumboldt M, Rumboldt Z. Smoking cessation with nicotine replacement therapy among health care workers: randomized double-blind study. Croat Med J 2003; 44: 219-24.
51. Shiffman S, Dresler CM, Hajek P, et al. Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med 2002; 162: 1267-76.
52. Hall SM, Humfleet GL, Reus VI, et al. Psychological intervention and antidepressant treatment in smoking cessation. Arch Gen Psychiatry 2002; 59: 930-6.
53. Glover ED, Glover PN, Franzon M, et al. A comparison of a nicotine sublingual tablet and placebo for smoking cessation. Nicotine Tob Res 2002; 4: 441-50.
54. Ahluwalia JS, Harris KJ, Catley D, et al. Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial. JAMA 2002; 288: 468-74.
55. Gonzales DH, Nides MA, Ferry LH, et al. Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebocontrolled study. Clin Pharmacol Ther 2001; 69: 438-44.
56. Wallstrom M, Nilsson F, Hirsch JM. A randomized, double-blind, placebo-controlled clinical evaluation of a nicotine sublingual tablet in smoking cessation. Addiction 2000; 95: 1161-71.
57. Garvey AJ, Kinnunen T, Nordstrom BL, et al. Effects of nicotine gum dose by level of nicotine dependence. Nicotine Tob Res 2000; 2: 53-63.
58. Tonnesen P, Paoletti P, Gustavsson G, et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society. Eur Respir J 1999; 13: 238-46.
59. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340: 685-91.
60. Hughes JR, Lesmes GR, Hatsukami DK, et al. Are higher doses of nicotine replacement more effective for smoking cessation? Nicotine Tob Res 1999; 1: 169-74.
61. Hays JT, Croghan IT, Schroeder DR, et al. Over-the-counter nicotine patch therapy for smoking cessation: results from randomized, double-blind, placebo-controlled, and open label trials. Am J Public Health 1999; 89: 1701-7.
62. Daughton D, Susman J, Sitorius M, et al. Transdermal nicotine therapy and primary care. Importance of counseling, demographic, and participant selection factors on 1-year quit rates. The Nebraska Primary Practice Smoking Cessation Trial Group. Arch Fam Med 1998; 7: 425-30.
63. Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337: 1195-202.
64. Hjalmarson A, Nilsson F, Sjostrom L, et al. The nicotine inhaler in smoking cessation. Arch Intern Med 1997; 157: 1721-8.
65. Blondal T, Franzon M, Westin A. A double-blind randomized trial of nicotine nasal spray as an aid in smoking cessation. Eur Respir J 1997; 10: 1585-90.
66. Schneider NG, Olmstead R, Nilsson F, et al. Efficacy of a nicotine inhaler in smoking cessation: a double-blind, placebo-controlled trial. Addiction 1996; 91: 1293-306.
67. Paoletti P, Fornai E, Maggiorelli F, et al. Importance of baseline cotinine plasma values in smoking cessation: results from a double-blind study with nicotine patch. Eur Respir J 1996; 9: 643-51.
68. Hall SM, Munoz RF, Reus VI, et al. Mood management and nicotine gum in smoking treatment: a therapeutic contact and placebo-controlled study. J Consult Clin Psychol 1996; 64: 1003-9.
69. Stapleton JA, Russell MA, Feyerabend C, et al. Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practice. Addiction 1995; 90: 31-42.
70. Schneider NG, Olmstead R, Mody FV, et al. Efficacy of a nicotine nasal spray in smoking cessation: a placebo-controlled, double-blind trial. Addiction 1995; 90: 1671-82.
71. Kornitzer M, Boutsen M, Dramaix M, et al. Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. Prev Med 1995; 24: 41-7.
72. Herrera N, Franco R, Herrera L, et al. Nicotine gum, 2 and 4 mg, for nicotine dependence. A double-blind placebo-controlled trial within a behavior modification support program. Chest 1995; 108: 447-51.
73. Gourlay SG, Forbes A, Marriner T, et al. Double blind trial of repeated treatment with transdermal nicotine for relapsed smokers. BMJ 1995; 311: 363-6.
74. Hurt RD, Dale LC, Fredrickson PA, et al. Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. One-year outcome and percentage of nicotine replacement. JAMA 1994; 271: 595-600.
75. Hjalmarson A, Franzon M, Westin A, et al. Effect of nicotine nasal spray on smoking cessation. A randomized, placebo-controlled, double-blind study. Arch Intern Med 1994; 154: 2567-72.
76. Fiore MC, Kenford SL, Jorenby DE, et al. Two studies of the clinical effectiveness of the nicotine patch with different counseling treatments. Chest 1994; 105: 524-33.
77. Westman EC, Levin ED, Rose JE. The nicotine patch in smoking cessation. A randomized trial with telephone counseling. Arch Intern Med 1993; 153: 1917-23.
78. Tonnesen P, Norregaard J, Mikkelsen K, et al. A double-blind trial of a nicotine inhaler for smoking cessation. JAMA 1993; 269: 1268-71.
79. Sachs DP, Sawe U, Leischow SJ. Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group counseling. Arch Intern Med 1993; 153: 1881-90.
80. Anon. Effectiveness of a nicotine patch in helping people stop smoking: results of a randomised trial in general practice. Imperial Cancer Research Fund General Practice Research Group. BMJ 1993; 306: 1304-8.
81. Sutherland G, Stapleton JA, Russell MA, et al. Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet 1992; 340: 324-9.
82. Tonnesen P, Norregaard J, Simonsen K, et al. A double-blind trial of a 16-hour transdermal nicotine patch in smoking cessation. N Engl J Med 1991; 325: 311-15.
83. Daughton DM, Heatley SA, Prendergast JJ, et al. Effect of transdermal nicotine delivery as an adjunct to low-intervention smoking cessation therapy. A randomized, placebo-controlled, double-blind study. Arch Intern Med 1991; 151: 749-52.
84. Killen JD, Fortmann SP, Newman B, et al. Evaluation of a treatment approach combining nicotine gum with self-guided behavioral treatments for smoking relapse prevention. J Consult Clin Psychol 1990; 58: 85-92.
85. Hall SM, Tunstall CD, Ginsberg D, et al. Nicotine gum and behavioral treatment: a placebo controlled trial. J Consult Clin Psychol 1987; 55: 603-5.
86. Hjalmarson AI. Effect of nicotine chewing gum in smoking cessation. A randomized, placebo-controlled, double-blind study. JAMA 1984; 252: 2835-8.
87. Hughes JR, Gust SW, Keenan RM, et al. Nicotine vs placebo gum in general medical practice. JAMA 1989; 261: 1300-5.
88. Jamrozik K, Fowler G, Vessey M, et al. Placebo controlled trial of nicotine chewing gum in general practice. Br Med J (Clin Res Ed) 1984; 289: 794-7.
89. Jarvik ME, Schneider NG. Degree of addiction and effectiveness of nicotine gum therapy for smoking. Am J Psychiatry 1984; 141: 790-1.
90. Jarvis MJ, Raw M, Russell MA, et al. Randomised controlled trial of nicotine chewing-gum. Br Med J (Clin Res Ed) 1982; 285: 537-40.
91. Malcolm RE, Sillett RW, Turner JA, et al. The use of nicotine chewing gum as an aid to stopping smoking. Psychopharmacology (Berl) 1980; 70: 95-6.
92. Schneider NG, Jarvik ME, Forsythe AB, et al. Nicotine gum in smoking cessation: a placebo-controlled, double-blind trial. Addict Behav 1983; 8: 253-61.
93. Abelin T, Buehler A, Muller P, et al. Controlled trial of transdermal nicotine patch in tobacco withdrawal. Lancet 1989; 1: 7-10.
94. Fortmann SP, Killen JD, Telch MJ, et al. Minimal contact treatment for smoking cessation. A placebo controlled trial of nicotine polacrilex and self-directed relapse prevention: initial results of the Stanford Stop Smoking Project. JAMA 1988; 260: 1575-80.
95. Leeman RF, Huffman CJ, O'Malley SS. Alcohol history and smoking cessation in nicotine replacement therapy, bupropion sustained release and varenicline trials: a review. Alcohol Alcohol 2007; 42: 196-206.
96. Lutsenko H, Doran CM, Hall WD. Australian smokers' use of bupropion and nicotine replacement therapies and their relation to reimbursement, Australia 2001-05. Drug Alcohol Rev 2008; 27: 160-4.
97. Hudson JI, Hiripi E, Pope HG Jr, et al. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry 2007; 61: 348-58.
98. Hurt RD, Offord KP, Croghan IT, et al. Mortality following inpatient addictions treatment. Role of tobacco use in a community-based cohort. JAMA 1996; 275: 1097-103.
99. Le Strat Y, Ramoz N, Gorwood P. In alcohol-dependent drinkers, what does the presence of nicotine dependence tell us about psychiatric and addictive disorders comorbidity? Alcohol Alcohol 2010; 45: 167-72.